Rankings / Weight Loss — Incretins & Amylin
Setmelanotide
Weight loss · MC4R agonist
Tier B+
What this is
Only approved for specific rare genetic obesity syndromes (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). In POMC trial: 80% achieved ≥10% weight loss. Not a general obesity drug — requires genetic testing.
Mechanism
Selective melanocortin-4 receptor agonist; reactivates MC4R signaling in POMC-deficient, LEPR-deficient, PCSK1-deficient, or BBS patients; hypothalamic appetite suppression
Dose & route
Imcivree: 2-3 mg SC daily
Citations
- https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30364-8/abstract
- https://pubmed.ncbi.nlm.nih.gov/33137293/
- https://www.ncbi.nlm.nih.gov/books/NBK589641/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.